E15 VC
VC Fund
Central, Hong Kong
E15 VC is a stage and geographically agnostic venture capital firm
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries E15 VC invests in
Stages E15 VC invests in
Countries E15 VC invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $1.3M–$5M
- Series A
- $13M–$14M
- Series D
- $280M–$351M
Investment Focus
Industry
- Health Care 4 (36%)
- Medical 3 (27%)
- Robotics 2 (18%)
- Biotechnology 2 (18%)
- mHealth 1 (9%)
Stage
- Seed 3 (27%)
- Series A 2 (18%)
- Series D 2 (18%)
- Pre-Seed 1 (9%)
- Series B 1 (9%)
Country
- United States 5 (45%)
- Ireland 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Philip Liang
Managing Partner
|
Managing Partner | Total investments: 5 | Find email | |
|
Shrikant Patnaik
Principal
|
Principal | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Eikon Therapeutics
|
Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications. | $350.7M / Series D / Feb 26, 2025 | |
Fluent Metal
|
Fluent Metal is a company that makes metal 3D printing economical, efficient, and safe. | $3.2M / Seed / Mar 14, 2024 | |
|
Eikon Therapeutics
|
Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications. | $517.8M / Series B / Jan 06, 2022 | |
Vicarious Surgical
|
Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goal of increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs. | $142M / Post-IPO Equity / Sep 20, 2021 | |
Frankie Health
|
Frankie gets high-quality support to employees with a few clicks and without needing to tell anyone else about it and uses a proactive and personalized approach to mental healthcare with underlying predictive models. | $1.3M / Seed / Jan 11, 2021 | |
|
Vicarious Surgical
|
Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goal of increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs. | $13.2M / Series A / Aug 07, 2020 | |
|
Frankie Health
|
Frankie gets high-quality support to employees with a few clicks and without needing to tell anyone else about it and uses a proactive and personalized approach to mental healthcare with underlying predictive models. | $250K / Pre-Seed / Jul 01, 2019 | |
Home Bay Technologies
|
HomeBay is a guided solution that makes it easy for homeowners to market and sell their property without the use or cost of a listing agent.Homeowners can list their home for sale in less time than it takes to meet with a realtor. Home Bay then syndicate their listing to every site that matters from popular sites like Zillow, Trulia, Yahoo!Homes, and Realtor.com to thousands of local agency and brokerage sites.Sellers manage their listings, open tasks, open houses, showings, and the incoming buyer offers directly from their dashboard. They can also receive and counter buyer offers with guided, in-form intelligence that is localized to their zip code. This guided transaction experience is akin to TurboTax, but applied to real estate forms. | $13.5M / Series A / Jan 03, 2019 | |
Auris Health
|
Auris Health engages in the development of robotics technology for medical applications. The company designs a novel dual-arm micro-surgical system for ophthalmic surgery. The company focuses on transforming medical intervention by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform. It wasfounded in 2007 and headquartered in Redwood City, California. | $220M / Series E / Nov 28, 2018 | |
|
Auris Health
|
Auris Health engages in the development of robotics technology for medical applications. The company designs a novel dual-arm micro-surgical system for ophthalmic surgery. The company focuses on transforming medical intervention by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform. It wasfounded in 2007 and headquartered in Redwood City, California. | $280.2M / Series D / Aug 04, 2017 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does E15 VC invest in?
E15 VC invests primarily in Health Care, Medical and Robotics startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is E15 VC's check size?
E15 VC typically joins rounds of $1.3M–$5M at Seed, $13M–$14M at Series A and $280M–$351M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds E15 VC participates in.
How do I contact E15 VC?
Public channels for E15 VC include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at E15 VC?
The team at E15 VC includes Philip Liang (Managing Partner) and Shrikant Patnaik (Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
